Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

NCT04100694 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

NRG1 Fusion
Pancreatic Cancer
Non Small Cell Lung Cancer
Solid Tumor, Unspecified, Adult
Prostate Cancer
Head and Neck Cancer
Colorectal Cancer
Breast Cancer
Cholangiocarcinoma
Renal Cell Carcinoma
Unknown Primary Tumors

Interventions

DRUG: MCLA-128

Sponsor

Merus B.V.